Insider Selling: Natera, Inc. (NASDAQ:NTRA) CEO Sells 1,709 Shares of Stock

by · The Cerbat Gem

Natera, Inc. (NASDAQ:NTRA – Get Free Report) CEO Steven Leonard Chapman sold 1,709 shares of the company’s stock in a transaction on Monday, October 21st. The shares were sold at an average price of $120.76, for a total value of $206,378.84. Following the completion of the sale, the chief executive officer now owns 194,615 shares in the company, valued at $23,501,707.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

  • On Tuesday, October 15th, Steven Leonard Chapman sold 4,523 shares of Natera stock. The shares were sold at an average price of $130.40, for a total value of $589,799.20.
  • On Monday, September 16th, Steven Leonard Chapman sold 5,024 shares of Natera stock. The shares were sold at an average price of $128.48, for a total value of $645,483.52.
  • On Thursday, August 15th, Steven Leonard Chapman sold 5,583 shares of Natera stock. The shares were sold at an average price of $118.91, for a total value of $663,874.53.
  • On Monday, July 29th, Steven Leonard Chapman sold 4,084 shares of Natera stock. The shares were sold at an average price of $102.77, for a total value of $419,712.68.

Natera Stock Down 0.5 %

Shares of NTRA stock traded down $0.55 during trading hours on Tuesday, reaching $119.95. The company had a trading volume of 718,795 shares, compared to its average volume of 1,334,780. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. Natera, Inc. has a twelve month low of $36.90 and a twelve month high of $133.54. The company has a market capitalization of $14.73 billion, a P/E ratio of -38.45 and a beta of 1.53. The stock’s fifty day simple moving average is $123.43 and its 200 day simple moving average is $110.98.

Natera (NASDAQ:NTRA – Get Free Report) last posted its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The business had revenue of $413.35 million during the quarter, compared to analyst estimates of $343.00 million. During the same quarter last year, the firm earned ($0.97) earnings per share. The company’s revenue for the quarter was up 58.1% compared to the same quarter last year. As a group, sell-side analysts expect that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Canaccord Genuity Group upped their target price on Natera from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, August 27th. UBS Group dropped their target price on Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research note on Friday, August 9th. The Goldman Sachs Group upped their target price on Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. StockNews.com upgraded Natera from a “sell” rating to a “hold” rating in a research note on Thursday, October 17th. Finally, TD Cowen upped their target price on Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, August 9th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and a consensus price target of $124.44.

View Our Latest Analysis on NTRA

Institutional Investors Weigh In On Natera

Large investors have recently modified their holdings of the stock. Itau Unibanco Holding S.A. purchased a new position in Natera in the second quarter valued at about $28,000. Quarry LP boosted its holdings in Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 108 shares during the last quarter. Tobam purchased a new position in Natera in the second quarter valued at about $74,000. Finally, DekaBank Deutsche Girozentrale purchased a new position in Natera in the first quarter valued at about $83,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

(Get Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Featured Stories